FDA Clears IND for First Dual-Targeting In Vivo CAR-T Therapy
LEGN sits 18% above its 52-week low of $16.24.
Summary
Legend Biotech received FDA clearance of its IND for LB2501, a first-of-its-kind in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell malignancies. The therapy is designed as an off-the-shelf, single-infusion treatment that generates CAR-T cells directly within the patient, potentially eliminating several manufacturing steps required for conventional autologous CAR-T and avoiding lymphodepleting chemotherapy. A U.S. Phase 1/2 study will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy. This follows the October 13th 6-K reporting preliminary Q3 CARVYKTI net trade sales of approximately $710 million, up from $657 million in Q2, and the September 14th pipeline update that flagged a new in vivo BCMA program. The clearance advances Legend's next-generation cell engineering platform beyond its current CARVYKTI franchise, though LB2501 remains early-stage with the U.S. study not yet underway.
Updates
· SEC 6-K — LB2501 is the first known dual-targeting in vivo CAR-T to receive FDA IND clearance; the planned U.S. Phase 1/2 study will assess safety, tolerability, pharmacokinetics and preliminary efficacy.
At the time of this announcement, LEGN was trading at $19.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $16.24 to $37.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.